Clinical trial
A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.
NCT02499627 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.
- Lead sponsor
- Fondazione Italiana Linfomi - ETS
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 23, 2015
- Completion date
- June 30, 2020
- Enrollment
- 43 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.